<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00252798</url>
  </required_header>
  <id_info>
    <org_study_id>D7913C00073</org_study_id>
    <secondary_id>1839IL/0073</secondary_id>
    <nct_id>NCT00252798</nct_id>
  </id_info>
  <brief_title>ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Trial to Evaluate ZD1839(Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to determine the Maximum tolerated dose, if any, of the
      combination of daily ZD1839 250 mg with carboplatin AUC 2 and 60 Gray (Gy) irradiation and up
      to 45 mg/m2 paclitaxel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the Maximum tolerated dose, if any, of the combination of daily ZD1839 250 mg with carboplatin AUC 2 and 60 Gray (Gy) irradiation and up to 45 mg/m2 paclitaxel.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the activity potential of the combination of ZD1839, carboplatin, paclitaxel &amp; radiation therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimating the objective response rate (complete response [CR] &amp; partial response [PR]) as assessed by positron emission tomography with (18F)-labelled fluorodeoxyglucose (PET-FDG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the objective response rate (CR and PR) as assessed by computerised tomography (CT) scan</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the complete response rate (CR) as assessed by PET-FDG</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate progression free survival (PFS) as assessed by clinical examination, chest x-ray, CT scan ± PET-FDG</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterise the safety and tolerability of ZD1839 combined with concurrent carboplatin, paclitaxel and radiation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the site of first failure (characterised as local-regional, distant or both)</measure>
  </secondary_outcome>
  <enrollment>44</enrollment>
  <condition>Non Small Cell Lung Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically or cytologically confirmed locally advanced stage IIIA or
             IIIB NSCLC (without pleural effusion)

          -  Patients with apical tumours and supraclavicular nodes are acceptable if both can be
             easily encompassed in one radiation field

          -  Minimum life expectancy with treatment of 6 months

          -  WHO performance status 0-1

        Exclusion Criteria:

          -  Patients with previous malignancies other than NSCLC

          -  Previous radiotherapy for NSCLC

          -  Previous immunotherapy or chemotherapy

          -  Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer
             therapy

          -  Forced expiratory volume in 1 second (FEV1) less than 1 litre (L)

          -  Absolute neutrophil count (ANC) less than 1.5 x 109/L or platelets less than 100 x
             109/L

          -  Serum bilirubin greater than 1.25 times the upper limit of reference range

          -  ALT or AST greater than 2.5 times the ULRR
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Australia Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woolloonabba</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2005</study_first_submitted>
  <study_first_submitted_qc>November 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>December 16, 2007</last_update_submitted>
  <last_update_submitted_qc>December 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2007</last_update_posted>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

